Moderate to Severe Psoriatic Arthritis
Conditions
Keywords
Psoriatic arthritis, Psoriasis, bDMARD, csDMARD, ACR50, Molecular Glue Degrader, VAV1
Brief summary
The purpose of this Phase 2a/b study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). 2. to determine the dose-response relationship of DDY391 in participants with PsA to support dose selection for Phase 3.
Detailed description
This study is a Phase 2a/b, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy, safety, tolerability and dose-response relationship of DDY391 in participants with active moderate to severe PsA. The study is composed of two sequential parts: * Part A to evaluate efficacy, safety and tolerability of DDY391 compared with placebo. * Part B to determine the dose-response relationship of multiple doses of DDY391 compared with placebo.
Interventions
DRUGDDY391
DDY391
DRUGPlacebo
Matching placebo
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Female or male participants at least 18 years of age. * Diagnosis of PsA and meeting classification criteria for Psoriatic arthritis (CASPAR) at screening. * Moderate to severe PsA at screening and baseline. Key
Exclusion criteria
* Presence of inflammatory conditions other than psoriasis or PsA including but not limited to those associated with arthralgia or arthritis (e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, sarcoidosis) or presence of fibromyalgia or osteoarthritis with articular symptoms. * Use of bDMARD treatment within 4 weeks or 5 half-lives of randomization, whichever is longer * Prior use of JAK inhibitors or TYK2 inhibitors (e.g., deucravacitinib). Prior use of apremilast is allowed but must not be taken within 4 weeks of baseline. * Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to baseline. * History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed). * Any active viral, bacterial or other infections at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Number of participants achieving American College of Rheumatology 50 (ACR50) response | Week 12 | To evaluate the efficacy of DDY391 versus placebo through achievement of ACR 50. ACR 50 is a validated tool for assessing RA disease activity. |
| Part A and B: Number of participants achieving American College of Rheumatology 50 (ACR50) response | Week 12 | To demonstrate the dose-response relationship of DDY391 compared to placebo in bDMARD-IR participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part B: Number of participants achieving American College of Rheumatology 50 (ACR50) response | Week 12 | To demonstrate the dose-response relationship of DDY391 compared to placebo in participants. |
| Part A and Part B: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From first dose through Week 12 | Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. |
Countries
United States
Contacts
CONTACTNovartis Pharmaceuticals
Outcome results
None listed